Tengfei Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tengfei Li has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Fengzhen Li
Department of Otolaryngology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, PR China
2 shared publications- Huanhai Liu
Department of Otolaryngology The Second Affiliated Hospital of the Naval Military University (Shanghai Changzheng Hospital) Shanghai China
2 shared publications Tian‐Yu Wang
Department of Otolaryngology, Changzheng Hospital Naval Medical University/Second Military Medical University Shanghai China
2 shared publications- Boyu Cai
Department of Otolaryngology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, PR China
1 shared publication Caiquan Liang
Department of Otolaryngology, Changzheng Hospital, Naval Medical University (Second Military Medical University), Shanghai, China
1 shared publicationCai‐Quan Liang
Department of Otorhinolaryngology, Changzheng Hospital Naval Medical University (Second Military Medical University) Shanghai China
1 shared publication
Latest Publications
- Open Access
- 29 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
IL-17a induces age-related olfactory dysfunction by impairing regeneration and promoting respiratory metaplasia in mice
The olfactory epithelium (OE) undergoes life-long renewal and regeneration. This process is supported by the globose basal cells (GBC) during the homeostatic state, as well as horizontal basal cells (HBC) during severe damage. Inflamm-aging refers to the low-grade, chronic and progressive state of heightened pro-inflammation associated with aging. However, the impact of inflamm-aging on OE homeostasis, regeneration, and the inflammatory microenvironment is not fully understood. In this study using mouse models, we elucidate the role of interleukin-17a (IL-17a) in OE regeneration and olfactory function. Our findings implicate that inflamm-aging in aged OE promotes the recruitment and activation of immune cells, accompanied by crosstalk between HBC and T cells. Elevated expression of IL-17a in aged OE triggers inflammatory signals and impairs olfactory function. Administration of IL-17a inhibitor Y-320 or neutralizing antibody promotes sensory neuronal regeneration and reverses age-related respiratory metaplasia in OE. Co-culturing mouse OE organoids with Th17 cells impairs neuronal generation and enhances the transformation towards respiratory cells, while neutralizing antibody against IL-17a alleviates neuronal loss and respiratory transformation. Additionally, conditional knockout of IL-17a in T cells facilitates OE regeneration by promoting HBC recruitment and differentiation into GBC. Collectively, our study identifies a function of IL-17a in OE regeneration and age-related deficits in olfactory function, providing evidence for further investigation of IL-17a as a possible therapeutic target against presbyosmia.
- 29 December 2025
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessIL-17a induces age-related olfactory dysfunction by impairing regeneration and promoting respiratory metaplasia in mice
The olfactory epithelium (OE) undergoes life-long renewal and regeneration. This process is supported by the globose basal cells (GBC) during the homeostatic state, as well as horizontal basal cells (HBC) during severe damage. Inflamm-aging refers to the low-grade, chronic and progressive state of heightened pro-inflammation associated with aging. However, the impact of inflamm-aging on OE homeostasis, regeneration, and the inflammatory microenvironment is not fully understood. In this study using mouse models, we elucidate the role of interleukin-17a (IL-17a) in OE regeneration and olfactory function. Our findings implicate that inflamm-aging in aged OE promotes the recruitment and activation of immune cells, accompanied by crosstalk between HBC and T cells. Elevated expression of IL-17a in aged OE triggers inflammatory signals and impairs olfactory function. Administration of IL-17a inhibitor Y-320 or neutralizing antibody promotes sensory neuronal regeneration and reverses age-related respiratory metaplasia in OE. Co-culturing mouse OE organoids with Th17 cells impairs neuronal generation and enhances the transformation towards respiratory cells, while neutralizing antibody against IL-17a alleviates neuronal loss and respiratory transformation. Additionally, conditional knockout of IL-17a in T cells facilitates OE regeneration by promoting HBC recruitment and differentiation into GBC. Collectively, our study identifies a function of IL-17a in OE regeneration and age-related deficits in olfactory function, providing evidence for further investigation of IL-17a as a possible therapeutic target against presbyosmia.
- Open Access
- 8 September 2025
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 12 (4) , 494-504
Cellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis
Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma control, and adversely affects quality of life and productivity in both work and school environments. Prevention and treatment strategies for AR encompass various approaches, including allergen avoidance, pharmacotherapy, allergen‐specific immunotherapy (AIT), and patient education. Among the treatments for AR, AIT stands out as the only curative intervention. It offers a targeted and long‐term solution by modifying the underlying immune response, providing lasting relief for individuals with AR. AIT, which targets individual allergens, is garnering increasing attention due to recent evidence from numerous randomized controlled trials and long‐term real‐life studies that attest to its effectiveness. By actively altering the immune response, AIT modifies the natural course of allergy, offering benefits that extend beyond the immediate symptom relief. In this updated review, we provide new insights into the roles of diverse immune cells involved in AIT for the treatment of AR. AIT inhibits FcεRⅠactivity, enhances epithelial function, reduces pro‐inflammatory ILC2s while promoting immunoregulatory IL‐10+ILC2s, augments regulatory DCreg subsets, and drives a shift from Th2 to Th1 immune responses. The objective of this review is to explore the fundamental principles and effectiveness of immunotherapy in the management of AR, as well as to showcase the latest developments in this area of research.
- 8 September 2025
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 12 (4) , 494-504
Open AccessCellular Mechanism and Key Insights in Allergen Immunotherapy for Allergic Rhinitis
Allergic rhinitis (AR) arises from immune responses mediated by immunoglobulin E (IgE) to inhaled allergens, representing one of the most prevalent chronic conditions worldwide. Although AR may not be a serious ailment, it holds clinical relevance as it underpins numerous complications, serves as a major risk factor for suboptimal asthma control, and adversely affects quality of life and productivity in both work and school environments. Prevention and treatment strategies for AR encompass various approaches, including allergen avoidance, pharmacotherapy, allergen‐specific immunotherapy (AIT), and patient education. Among the treatments for AR, AIT stands out as the only curative intervention. It offers a targeted and long‐term solution by modifying the underlying immune response, providing lasting relief for individuals with AR. AIT, which targets individual allergens, is garnering increasing attention due to recent evidence from numerous randomized controlled trials and long‐term real‐life studies that attest to its effectiveness. By actively altering the immune response, AIT modifies the natural course of allergy, offering benefits that extend beyond the immediate symptom relief. In this updated review, we provide new insights into the roles of diverse immune cells involved in AIT for the treatment of AR. AIT inhibits FcεRⅠactivity, enhances epithelial function, reduces pro‐inflammatory ILC2s while promoting immunoregulatory IL‐10+ILC2s, augments regulatory DCreg subsets, and drives a shift from Th2 to Th1 immune responses. The objective of this review is to explore the fundamental principles and effectiveness of immunotherapy in the management of AR, as well as to showcase the latest developments in this area of research.
- Open Access
- 3 February 2024
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 10 (3) , 173-179
A cross‐sectional study on predictors of patients' tinnitus severity
Objective: To identify factors that influence the severity of tinnitus via a hierarchical multiple linear regression model.Methods: The study was a retrospective cross‐sectional analysis. The study included 331 patients experiencing tinnitus as their primary concern, who visited Shanghai Changzheng Hospital of the Navy Medical University between 2019 and 2021. Data on general health status and disease characteristics were collected from all patients. With their consent, participants underwent audiological evaluatons and completed questionnaires to analyze the characteristics of their tinnitus and the factors influencing its severity.Results: The correlation analysis showed a positive relationship between tinnitus frequency, tinnitus loudness, SAS scores, and PSQI scores with THI scores (P < 0.05) among nine examined variables (gender, handedness, employment status, age, BMI, tinnitus frequency, tinnitus loudness, SAS scores, and PSQI scores). The variables that were extracted from the multiple regression were; for the constant; β = −51.797, t = −4.484, P < 0.001, variable is significant; for the tinnitus loudness; β = 0.161, t = 2.604, P < 0.05, variable is significant; for the tinnitus frequency; β = 0.000, t = 1.269, P = 0.206, variable is not significant; for the SAS scores; β = 1.310, t = 7.685, P < 0.001, variable is significant; for the PSQI scores; β = 1.680, t = 5.433, P < 0.001, variable is significant. Therefore, the most accurate model for predicting severity in tinnitus patients is a linear combination of the constant, tinnitus loudness, SAS scores, and PSQI scores, Y(Tinnitus severity) = β0 + β1(Tinnitus loudness) + β2(SAS scores) + β3(PSQI scores). β0, β1, β2, and β3 are −51.797, 0.161, 1.310 and 1.680, respectively.Conclusion: Tinnitus severity is positively associated with loudness, anxiety levels, and sleep quality. To effectively manage tinnitus in patients, it is essential to promptly identify and address these accompanying factors and related symptoms.
- 3 February 2024
- Published by Wiley in World Journal of Otorhinolaryngology - Head and Neck Surgery
- Vol. 10 (3) , 173-179
Open AccessA cross‐sectional study on predictors of patients' tinnitus severity
Objective: To identify factors that influence the severity of tinnitus via a hierarchical multiple linear regression model.Methods: The study was a retrospective cross‐sectional analysis. The study included 331 patients experiencing tinnitus as their primary concern, who visited Shanghai Changzheng Hospital of the Navy Medical University between 2019 and 2021. Data on general health status and disease characteristics were collected from all patients. With their consent, participants underwent audiological evaluatons and completed questionnaires to analyze the characteristics of their tinnitus and the factors influencing its severity.Results: The correlation analysis showed a positive relationship between tinnitus frequency, tinnitus loudness, SAS scores, and PSQI scores with THI scores (P < 0.05) among nine examined variables (gender, handedness, employment status, age, BMI, tinnitus frequency, tinnitus loudness, SAS scores, and PSQI scores). The variables that were extracted from the multiple regression were; for the constant; β = −51.797, t = −4.484, P < 0.001, variable is significant; for the tinnitus loudness; β = 0.161, t = 2.604, P < 0.05, variable is significant; for the tinnitus frequency; β = 0.000, t = 1.269, P = 0.206, variable is not significant; for the SAS scores; β = 1.310, t = 7.685, P < 0.001, variable is significant; for the PSQI scores; β = 1.680, t = 5.433, P < 0.001, variable is significant. Therefore, the most accurate model for predicting severity in tinnitus patients is a linear combination of the constant, tinnitus loudness, SAS scores, and PSQI scores, Y(Tinnitus severity) = β0 + β1(Tinnitus loudness) + β2(SAS scores) + β3(PSQI scores). β0, β1, β2, and β3 are −51.797, 0.161, 1.310 and 1.680, respectively.Conclusion: Tinnitus severity is positively associated with loudness, anxiety levels, and sleep quality. To effectively manage tinnitus in patients, it is essential to promptly identify and address these accompanying factors and related symptoms.
- 1 May 2023
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 29 (19) , 1497-1503
A Systematic Review and Meta-analysis of the Effects of Topical Tranexamic Acid versus Topical Vasoconstrictors on the Management of Epistaxis
Objective: We aimed to evaluate the effectiveness of topical tranexamic acid (TXA) versus topical vasoconstrictors in the management of epistaxis via a systematic review and meta-analysis. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards were followed for the meta-analysis. We systematically searched Embase, Web of Science, Cochrane Library, CNKI, and PubMed for randomized controlled trials (from inception to August 2022; no language restrictions), comparing the effect of topical TXA and topical vasoconstrictors on the treatment of epistaxis. The Q test was used to evaluate heterogeneity, and funnel plots were utilized to identify bias. For the meta-analysis, the fixed-effects model was employed, and the t-test was utilized to determine significance. Results: Of 1012 identified studies, 5 were found to be eligible for our analysis. In total, 598 patients were included; 297 of them received TXA and 301 received vasoconstrictors. Hemostasis was more likely to be achieved at the first re-assessment in patients treated with TXA. Subgroup analysis indicated patients treated with TXA to have less likelihood of bleeding recurrence, compared to patients treated with vasoconstrictors. The detected time interval of rebleeding was 10 min, between 24h to 72h, and after 7 days, respectively, and the differences were significant between the two groups of patients treated with TXA and vasoconstrictors. Conclusion: Topical TXA was associated with better post-treatment hemorrhagic arrest rates compared to topical vasoconstrictors in the management of epistaxis.
- 1 May 2023
- Published by Bentham Science Publishers Ltd. in Current Pharmaceutical Design
- Vol. 29 (19) , 1497-1503
A Systematic Review and Meta-analysis of the Effects of Topical Tranexamic Acid versus Topical Vasoconstrictors on the Management of Epistaxis
Objective: We aimed to evaluate the effectiveness of topical tranexamic acid (TXA) versus topical vasoconstrictors in the management of epistaxis via a systematic review and meta-analysis. Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards were followed for the meta-analysis. We systematically searched Embase, Web of Science, Cochrane Library, CNKI, and PubMed for randomized controlled trials (from inception to August 2022; no language restrictions), comparing the effect of topical TXA and topical vasoconstrictors on the treatment of epistaxis. The Q test was used to evaluate heterogeneity, and funnel plots were utilized to identify bias. For the meta-analysis, the fixed-effects model was employed, and the t-test was utilized to determine significance. Results: Of 1012 identified studies, 5 were found to be eligible for our analysis. In total, 598 patients were included; 297 of them received TXA and 301 received vasoconstrictors. Hemostasis was more likely to be achieved at the first re-assessment in patients treated with TXA. Subgroup analysis indicated patients treated with TXA to have less likelihood of bleeding recurrence, compared to patients treated with vasoconstrictors. The detected time interval of rebleeding was 10 min, between 24h to 72h, and after 7 days, respectively, and the differences were significant between the two groups of patients treated with TXA and vasoconstrictors. Conclusion: Topical TXA was associated with better post-treatment hemorrhagic arrest rates compared to topical vasoconstrictors in the management of epistaxis.